PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of arthrestherBioMed Centralbiomed central web sitesearchsubmit a manuscriptregisterthis articleArthritis Research & Therapy
 
Arthritis Res Ther. 2012; 14(3): R156.
Published online Jun 29, 2012. doi:  10.1186/ar3896
PMCID: PMC3446542
Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort
Bin Zhang,1 Bernard Combe,2 Nathalie Rincheval,2 and David T Felsoncorresponding author1,3
1Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA 02118, USA
2Department of Rheumatology, Lapeyronie Hospital, Montpellier I University, UMR 5535 Montpellier, France
3Arthritis Research UK Epidemiology Unit, University of Manchester, Manchester, M13 9PT, UK
corresponding authorCorresponding author.
Bin Zhang: binzhang/at/bu.edu; Bernard Combe: b-combe/at/chu-montpellier.fr; Nathalie Rincheval: nathalie.rincheval/at/inserm.fr; David T Felson: david.felson/at/manchester.ac.uk
Received March 5, 2012; Revised May 16, 2012; Accepted June 29, 2012.
Abstract
Introduction
In development of the American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) remission definitions using clinical trials data, one criterion used to compare different remission definitions was whether, compared with those not in remission, those in remission had evidence of later disease stability defined by x-ray and functional status. Validation of the RA remission criteria using observational study data is necessary before recommending their use in practice.
Methods
Using data from those who met RA criteria in the ESPOIR cohort, we matched each person in remission with a person not in remission and then carried out analyses comparing later stability of x-ray and health assessment questionnaire (HAQ) between the two groups. We compared the predictive validity of the same candidate definitions of remission evaluated in the ACR/EULAR process. To minimize potential bias and produce more stable results, we used a bootstrap resampling approach to select those not in remission, repeating the sample matching analysis process 500 times.
Results
Results were similar to those of clinical trials analyzed for the ACR/EULAR remission criteria. Specifically, the ACR/EULAR remission definitions using either an simple disease activity index (SDAI) ≤ 3.3, clinical disease activity index (CDAI) ≤ 2.8 or a definition of remission requiring tender joint count, swollen joint count, patient global assessment all ≤ 1 performed as well or better than other candidate definitions of remission in terms of predicting later x-ray and function stability.
Conclusions
ACR/EULAR definitions of remission developed for trials are similarly valid in observational studies in RA and could be used in practice.
Articles from Arthritis Research & Therapy are provided here courtesy of
BioMed Central